Please Wait
Applying Filters...
menu
    • menu
    AI drug discovery market to grow 30% CAGR, to reach US$ 35 bn by 2034; Novo, Lilly, BMS forge deals

    Data Compilation
    #PharmaFlow

    Pipeline Prospector Feb 2025: Bain buys Mitsubishi Tanabe for US$ 3.4 bn; Japan’s Ono gets FDA nod for rare joint tumor drug

    Stock Recap
    #PipelineProspector

    Menu

    5-chloro-N-[[(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl]methyl]thiophene-2-carboxamide

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 1,528Xls download

    Filters

    clear-filterReset all filters
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    Log in to access your PharmaMiles and download the data

    Last Updated on PharmaCompass Virtual Booth Country Certificate Holder Certificate No. Substance Issue Date Status Type End Date Substance No.
    24/02/2025 Polpharma
    Poland
    		 ZAKŁADY FARMACEUTYCZNE POLPHARMA S.A. Starogard Gdański PL CEP 2021-270 - Rev 03 Rivaroxaban, Non-micronised, Micronised 2024-08-23 Valid Chemical 2932
    24/02/2025 Moehs Iberica
    Spain
    		 Moehs Iberica S.L. Rubi ES CEP 2021-245 - Rev 01 Rivaroxaban, Micronised 2023-09-07 Valid Chemical 2932